Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 6/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3243999 | 0.87 | CYP1A2 (0.58) | CYP1A2KMOHTR2AHTR2CHTR2B | |
| SCHEMBL20083661 | 0.76 | CYP1A2 (0.62) | CYP1A2KMOHTR2AHTR2CHTR2B | |
| SCHEMBL29947768 | 0.76 | CYP1A2 (0.62) | CYP1A2KMOHTR2AHTR2CHTR2B | |
| SCHEMBL29487755 | 0.74 | CYP1A2 (0.47) | CYP1A2KMOHTR2AHTR2CHTR2B | |
| SCHEMBL30224567 | 0.73 | RECQL (0.42) | CYP1A2KMOHTR2AHTR2CP2RX7 | |
| SCHEMBL31301070 | 0.72 | CYP1A2 (0.57) | CYP1A2KMOHTR2AHTR2CHTR2B | |
| SCHEMBL8007547 | 0.72 | HTR2A (0.55) | CYP1A2KMOHTR2AHTR2CHTR2B | |
| SCHEMBL29353804 | 0.72 | CRHR1 (0.42) | CYP1A2KMORECQLADRA2ASMN1; SMN2 | |
| SCHEMBL319515 | 0.71 | RECQL (0.61) | CYP1A2KMOHTR2AHTR2CHTR2B | |
| SCHEMBL31429798 | 0.71 | CYP1A2 (0.55) | CYP1A2KMOHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | CYP1A2 3116/4885KMO 105/4885HTR2A 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.